Human Papilloma Virus (HPV) was studied widely in genital infections conquering the first place in etiology of uterine cervix cancer. Wide diffusion of HPV, caused by its simplicity of transmission, had determined the necessity of deep study of papilloma virus and its identification in other body districts, also oral cavity. The importance of HPV in world health is high, in fact high-risk HPV types contribute significantly to viral associated neoplasms, accounting for approximately 600,000 cases (5%) of cancers worldwide annually (1).

Differently from cervix cancer, HPV plays pathogenic role only in a small part of oral cancer through the continue expression of viral oncogene necessary for the histopathologic progression of malignant cancer HPV associated. Two proteins of HPV (E6 and E7) are the main responsible for cell transformation and malignant progression of cancer and so they are defined oncogene proteins (2). The action of oncogenic E6 and E7 proteins resides in the ability to inactivate two important tumor suppressor proteins, p53 and the retinoblastoma protein, pRB (3, 4).

A systematic meta-analysis reviewed the current
available literature in the field to determine the worldwide prevalence of HPV in Head and Neck Squamous Cell Carcinoma (HNSCC). Researchers analyzed 60 relevant studies using PCR detection from 26 countries. In all, 5,046 cases of SCCs (squamous cell carcinoma), 2,642 oral cancers, 969 oropharyngeal cancers, and 1,435 laryngeal cancers were studied. HPV prevalence was 35.6% in oropharyngeal cancers, 23.5% in oral cancers, and 24.0% in laryngeal cancers. The overall estimated prevalence of HPV in HNSCC was 26% (5).

In French retrospective multicenter study involved 12 centers located throughout the country it were included 185 histological samples collected from year 2000 to 2009 with a validated diagnosis of tonsil invasive carcinomas: HPV prevalence was 57% in tonsil cancers (6). Among the many high-risk HPV types, HPV-16 is the most common, found in almost 90% of the HPV(+) oropharyngeal cancers. At present, HPV-16 remains the only HPV type that is classified as cancer-causing in the head and neck (7).

For fairness, the Authors want to emphasize that results about the presence of HPV in Oral Squamous Cell Carcinoma (OSCC) were not the same in all studies, in fact in some studies the prevalence of HPV in OSCC was between 2-7% (8, 9).

The Human Papillomaviruses (HPVs) can be broadly grouped into cutaneous and mucosotropic types. The mucosotropic HPVs are typically found in the anogenital mucosa and oral mucosa. Genital infection with HPV can be transmitted to oral mucosa through autoinoculation, oral sex, or oral contact.

The virion is composed of a double-stranded, circular, 8,000-base pair DNA genome encased in a naked icosahedral capsid about 55 nm in diameter that comprise a heterogeneous family consisting of more than 130 different HPV types and 16 categories (10-13).

In this article we will analyze vary expression of HPV in oral cavity both benign and malignant, their prevalence and the importance in early diagnosis and prevention.
ally presents as multiple plaque-like or papular lesions, flat or convex, in the mucosa mostly of children. The color may vary from red to gray to white. Lesions occur on oral mucosa exclusively. The lesions are benign and may resolve spontaneously (Figure 4) (17, 18).

Other oral lesions that have been associated with human papillomavirus include erythroplakia (HPV-16), proliferative verrucous leukoplakia (HPV-16), candidal leukoplakia, oral squamous cell carcinoma (HPV-16 and HPV-19) and lichen planus (HPV-6, HPV-11 and HPV-16). Overall, HPV types 2, 4, 6, 11, 13 and 32 have been associated with benign oral lesions while HPV types 16 and 18 have been associated with malignant lesions.

It is now clear that high-risk human papillomavirus genotypes, particularly human papillomaviruses 16 and 18, are important co-factors, especially in cancers of the tonsils and elsewhere in the oropharynx.

A meta-analysis by the Fifth World Workshop on Oral Medicine reviewed 1,121 published studies of oral lesions. The odds ratio for association with high-risk human papillomaviruses and oral cancer was 4.0 (2.62-6.02) and that for oral potentially. The odds ratio for tobacco or heavy drinker and oral cancer was in a range between 3 and 9, so the odd ration of HPV underlines as it is an important risk factor.

Oral cancer shows highly variable clinical features. The most frequent appearance is a white lesion or red or ulcerative area. The clinical morphology is a function of the tumor growth, so you can observe exophytic lesions of papillary or warty appearance or growth endophytic lesions that take the form of penetrating ulcers (Figure 5). Oral cancer signs and symptoms list below considers both oral cancers from HPV and those from tobacco and alcohol: an ulcer or sore that does not heal within 2-3 weeks, difficult or painful swallowing, pain when chewing, a persistent sore
throat or hoarse voice, a swelling or lump in the mouth, a painless lump felt on the outside of the neck, which has been there for at least two weeks, a numb feeling in the mouth or lips, constant coughing, an ear ache on one side (unilateral) which persists for more than a few days (19-21).

**HPV contraction, and course**

Transmission of the virus can occur with direct contact, genital contact, anal and oral sex; latest studies suggest a salivary transmission and from mother to child during delivery.

The number of lifetime sexual partners is an important risk factor for the development of HPV-positive head-neck cancer. In case-control studies, the odds of HPV-positive throat cancer doubled in individuals who reported between one and five lifetime oral sexual partner. The risk increased five-fold in those patients with six or more oral sexual partners compared with those who have not had oral sex.

The virus may be inactive for weeks, months and for some people possibly even years after infection. There is no cure for the virus. Most of the time, HPV goes away by itself within two years and does not cause health problems. It is only when HPV stays in the body for many years that it might cause these oral cancers. Even then, it is a very small number of people that will have an HPV infection cascade all the way into an oral malignancy, though that number is increasing every year by about 10%. It is not known why HPV goes away in most, but not all cases. For
unknown reasons there is a small percentage of the population whose immune system does not recognize this as a threat and it is allowed to prosper (22-27).

Fortunately there is a difference between oropharyngeal cancer HPV+ and HPV-, the loss of the P16 expression by deletion, hypermethylation or mutation is common in OSCCs caused by alcohol and tobacco, producing injuries with a worse prognosis as they do not respond to chemotherapy or radiotherapy in the same way. E6 HPV’s oncoprotein can inactivate P53 too, although in these cases it would be a functional inactivation, not a mutation as it happens in cancer associated with tobacco and alcohol intake. In fact, the rate of P53 mutations due to HPV is very low.

All this would support the existing evidence of oral/oropharyngeal cancer etiologically associated with HPV having an increased survival and a better prognostic (85-90% to five years), but due to the transmission mode, patients with HPV associated HNSCC are younger (30-50 years old) (28-31).

Vaccine

HPV vaccine is the first explicitly designed to prevent virus induced cervix cancer (32, 33). HPVs 16 and 18 are the main targets of the currently approved vaccines and the available data confirm the success in the incidence reduction of pre-cancerous cervical injuries for these types (34).

The vaccine’s efficacy is limited by two factors since not all cancers are caused by HPVs 16 and 18; and there seems to be a requirement of vaccinating young women before they get infected by these two types. To be effective, such vaccination should start before “sexual puberty”. There are two commercially available prophylactic vaccines against HPV today: the bivalent (VPVs 16 and 18) Cervarix® and the tetravalent (VPVs 6,11,16 and 18) Gardasil®. Theoretically, there is no reason for these vaccines to fail to work against these same viruses in different localizations (such as oral cavity, pharynx, larynx or the anogenital region). Proving that the vaccine also prevents oropharyngeal cancer would mean not only a landmark in the prevention of these diseases, but it would also provide the missing link in the chain of evidences with the ultimate proof of HPV induced viral etiology of these tumors.

Vaccination is approved in females aged 9 to 26. The vaccination primary target population should be females aged 11 and 12. However the vaccine can also be administered to females up to 9 years old and to those aged between 13 and 26 who have been sexually active (35-37).

Last December 2014 new vaccine Gardasil 9 (VPVs 6, 11, 16, 18, 31, 33, 45, 52, 58) was approved in the United States, while it is still being considered by the European authorities that need to evaluate the efficacy and safety profile.

Conclusions

Considering the importance of HPV in influencing both the risk and the course of oral cancer, it assumes a fundamental importance the preventive diagnosis of HPV. In particular, the clinical examination of precancerous or cancerous lesions is not sufficient, but it is necessary an instrumental analysis. In addition to more traditional histological techniques performed on biopsies, you can now search for the viral DNA in skin cells flaking. It is thus evident the importance of early detection and dentists, rather than to other medical specialties, have a key responsibility of timely diagnostic classification of potentially malignant oral lesions.

The vaccine could be an important preventive strategy, in fact the scientific community is in agreement on hypothesis that blocking the contagion it may also limit the distance complications as the oropharyngeal cancer so in our opinion HPV is an important risk factor of sure future impact on world healthy.
References


Correspondence to:
Dr. Davide Testi
Graduate School in Materials for Health, Environment and Energy
University of Rome “Tor Vergata”, Rome, Italy
E-mail: davide_testi@hotmail.it